Sun Pharmaceutical FDA-483
FDA has released the FDA-483 with two observations from a 9/10-9/14 inspection at Sun Pharmaceuticals Industries, Punjab, India. The inspection observations were:
- the quality control unit lacks the responsibility and authority to approve and reject all in-process materials and drug products;
- the written stability testing program is not followed.